A citation-based method for searching scientific literature

Bhavna S Paratala, Jon H Chung, Casey B Williams, Bahar Yilmazel, Whitney Petrosky, Kirstin Williams, Alexa B Schrock, Laurie M Gay, Ellen Lee, Sonia C Dolfi, Kien Pham, Stephanie Lin, Ming Yao, Atul Kulkarni, Frances DiClemente, Chen Liu, Lorna Rodriguez-Rodriguez, Shridar Ganesan, Jeffrey S Ross, Siraj M Ali, Brian Leyland-Jones, Kim M Hirshfield. Nat Commun 2018
Times Cited: 52







List of co-cited articles
490 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
195
44

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
113
42

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
186
38

RET revisited: expanding the oncogenic portfolio.
Lois M Mulligan. Nat Rev Cancer 2014
293
36

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan. Nat Rev Clin Oncol 2018
134
36

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
570
36

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
615
36

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
896
34

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
272
30


Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
195
26

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Thomas Wiesner, Jie He, Roman Yelensky, Rosaura Esteve-Puig, Thomas Botton, Iwei Yeh, Doron Lipson, Geoff Otto, Kristina Brennan, Rajmohan Murali,[...]. Nat Commun 2014
368
26

Identification and characterization of RET fusions in advanced colorectal cancer.
Anne-France Le Rolle, Samuel J Klempner, Christopher R Garrett, Tara Seery, Eric M Sanford, Sohail Balasubramanian, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, Siraj M Ali,[...]. Oncotarget 2015
70
26

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.
P Ballerini, S Struski, C Cresson, N Prade, S Toujani, C Deswarte, S Dobbelstein, A Petit, H Lapillonne, E-F Gautier,[...]. Leukemia 2012
65
25

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
849
25

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta,[...]. Lancet Respir Med 2017
200
25

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
25

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
162
23

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
347
23

The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
568
23

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Alexander Drilon, Siqing Fu, Manish R Patel, Marwan Fakih, Ding Wang, Anthony J Olszanski, Daniel Morgensztern, Stephen V Liu, Byoung Chul Cho, Lyudmila Bazhenova,[...]. Cancer Discov 2019
67
23


Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.
Alena Skálová, Tomas Vanecek, Emmanuelle Uro-Coste, Justin A Bishop, Ilan Weinreb, Lester D R Thompson, Stefano de Sanctis, Marco Schiavo-Lena, Jan Laco, Cécile Badoual,[...]. Am J Surg Pathol 2018
66
21

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Qingling Huang, Valentina E Schneeberger, Noreen Luetteke, Chengliu Jin, Roha Afzal, Mikalai M Budzevich, Rikesh J Makanji, Gary V Martinez, Tao Shen, Lichao Zhao,[...]. Mol Cancer Ther 2016
52
21

Structure and physiology of the RET receptor tyrosine kinase.
Carlos F Ibáñez. Cold Spring Harb Perspect Biol 2013
98
21

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
171
21

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
F Pietrantonio, F Di Nicolantonio, A B Schrock, J Lee, F Morano, G Fucà, P Nikolinakos, A Drilon, J F Hechtman, J Christiansen,[...]. Ann Oncol 2018
51
19

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
203
19

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
M Santoro, F Carlomagno, A Romano, D P Bottaro, N A Dathan, M Grieco, A Fusco, G Vecchio, B Matoskova, M H Kraus. Science 1995
703
17

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Roberto Ferrara, Nathalie Auger, Edouard Auclin, Benjamin Besse. J Thorac Oncol 2018
92
17

A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Niho, Rakhee Chauhan, Phillip P Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki,[...]. Nat Commun 2018
52
17

Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.
Iván Plaza-Menacho, Karin Barnouin, Kerry Goodman, Rubén J Martínez-Torres, Annabel Borg, Judith Murray-Rust, Stephane Mouilleron, Phillip Knowles, Neil Q McDonald. Mol Cell 2014
45
20

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
S-H Lee, J-K Lee, M-J Ahn, D-W Kim, J-M Sun, B Keam, T M Kim, D S Heo, J S Ahn, Y-L Choi,[...]. Ann Oncol 2017
135
17

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Zofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, Justin F Gainor, Inga T Lennes, Viola W Zhu, Nicolas Marcoux, Mandeep K Banwait, Subba R Digumarthy, Wenjia Su,[...]. Cancer Discov 2018
213
17

NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?
Alena Skálová, Nikola Ptáková, Thalita Santana, Abbas Agaimy, Stephan Ihrler, Emmanuelle Uro-Coste, Lester D R Thompson, Justin A Bishop, Martina Baněčkova, Niels J Rupp,[...]. Am J Surg Pathol 2019
49
18

State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric-Bernstam. J Clin Oncol 2020
76
17

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
89
17


Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
I Plaza-Menacho, A Morandi, D Robertson, S Pancholi, S Drury, M Dowsett, L-A Martin, C M Isacke. Oncogene 2010
96
15

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Francesca Carlomagno, Teresa Guida, Suresh Anaganti, Giancarlo Vecchio, Alfredo Fusco, Anderson J Ryan, Marc Billaud, Massimo Santoro. Oncogene 2004
182
15

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
15

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
15

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, Robert C Doebele, Wade T Iams, Michael Oh, Victoria M Raymond, Richard B Lanman, Jonathan W Riess, Thomas E Stinchcombe,[...]. Clin Cancer Res 2019
39
20

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.
Julio C Ricarte-Filho, Sheng Li, Maria E R Garcia-Rendueles, Cristina Montero-Conde, Francesca Voza, Jeffrey A Knauf, Adriana Heguy, Agnes Viale, Tetyana Bogdanova, Geraldine A Thomas,[...]. J Clin Invest 2013
144
15


RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
76
15

Drug resistance profiles of mutations in the RET kinase domain.
Xuan Liu, Tao Shen, Blaine H M Mooers, Frank Hilberg, Jie Wu. Br J Pharmacol 2018
35
20

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
Taranjit S Gujral, Vinay K Singh, Zongchao Jia, Lois M Mulligan. Cancer Res 2006
55
13

Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.
Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C Roloff, Martin Schreiber, Neil Carragher, Kenneth K Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner,[...]. EMBO Mol Med 2013
54
13

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
Cristina Tognon, Stevan R Knezevich, David Huntsman, Calvin D Roskelley, Natalya Melnyk, Joan A Mathers, Laurence Becker, Fatima Carneiro, Nicol MacPherson, Doug Horsman,[...]. Cancer Cell 2002
583
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.